����ǰ��ĸ������������Ѫ��S100B���׺ͽ�����ά���Ե��׼�⼰���ٴ�����

Serum S100B protein and GFAP detection in neonates born to mothers with preeclampsia and its clinical significance.

??Abstract?? Objective To discuss the changes of S100B protein and GFAP levels and its relationship with 1 min Apgar scoring in the serum of neonates born to mothers with preeclampsia of different degrees. Methods From Oct.2012 to Mar.2013 in Chilren’s hospital of Shanxi province ?? 40 cases of newborns born to mothers with preeclampsia were divided into two groups: mild preeclampsia group ??L group 20 cases????severe preeclampsia group ??H group 20 cases????a healthy control group was established ??N group 20 cases????newborns of three groups were taken specimen at the time of admission ?? dual- antibody sandwich enzyme-linked immunosorbent assay ??ELISA?? was used to detect the level of serum GFAP and S100B . In the first three days after admission cranial ultrasound was performed in each child. Results The difference among the L??H and N group was statistically significant ??P2=17.20??P??0.05??; S100B and GFAP levels in L and H group were positively correlated ??γ= 0.658?? P??0.05??; S100B?? GFAP levels in L and H group and neonatal 1min Apgar score were negatively correlated ??γ$subScript$S100B$/subScript$=-0.482??γ$subScript$GFAP$/subScript$=-0.534??P??0.01??. Conclusion The more serious eclampsia?? the greater the possibility of brain damage?? and the more serious the elevation of S100B and GFAP levels?? and was negatively correlated with 1 min Apgar score?? which indicates that the possibility of S100B protein and GFAP as a predictor of neonatal brain injury deserves further study.